Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
101.58%
operating margin TTM
-39.86%
revenue TTM
42.83 Million
revenue per share TTM
0.72$
valuation ratios | |
|---|---|
| pe ratio | 5.82 |
| peg ratio | 0.00 |
| price to book ratio | 3.60 |
| price to sales ratio | 6.13 |
| enterprise value multiple | 6.01 |
| price fair value | 3.60 |
profitability ratios | |
|---|---|
| gross profit margin | 85.51% |
| operating profit margin | -39.86% |
| pretax profit margin | 109.09% |
| net profit margin | 101.58% |
| return on assets | 44.59% |
| return on equity | 81.34% |
| return on capital employed | -21.05% |
liquidity ratios | |
|---|---|
| current ratio | 4.89 |
| quick ratio | 4.84 |
| cash ratio | 2.03 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 47.59 |
| operating cycle | 113.55 |
| days of payables outstanding | 240.79 |
| cash conversion cycle | -127.25 |
| receivables turnover | 5.53 |
| payables turnover | 1.52 |
| inventory turnover | 7.67 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.00 |
| debt equity ratio | 0.01 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.01 |
| interest coverage | -6.32 |
| cash flow to debt ratio | 11.13 |
cash flow ratios | |
|---|---|
| free cash flow per share | 0.21 |
| cash per share | 1.64 |
| operating cash flow per share | 0.22 |
| free cash flow operating cash flow ratio | 0.94 |
| cash flow coverage ratios | 11.13 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | 16.56 |
Frequently Asked Questions
When was the last time Zevra Therapeutics, Inc. (NASDAQ:ZVRA) reported earnings?
Zevra Therapeutics, Inc. (ZVRA) published its most recent earnings results on 06-05-2026.
What is Zevra Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Zevra Therapeutics, Inc. (NASDAQ:ZVRA)'s trailing twelve months ROE is 81.34%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Zevra Therapeutics, Inc. (ZVRA) currently has a ROA of 44.59%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did ZVRA's net profit margin stand at?
ZVRA reported a profit margin of 101.58% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is ZVRA's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 4.89 in the most recent quarter. The quick ratio stood at 4.84, with a Debt/Eq ratio of 0.01.